|
KMID : 1200020200440010186
|
|
Diabetes & Metabolism Journal
2020 Volume.44 No. 1 p.186 ~ p.192
|
|
|
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
|
|
Kim Mi-Jin
Kim Na-Young
Jung Yun-A
Lee Seung-Hyeong
Jung Gwon-Soo
Kim Jung-Guk
Lee In-Kyu
Lee Sung-Woo
Choi Yeon-Kyung
Park Keun-Gyu
|
|
|
Abstract
|
|
|
|
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated protective effects against diabetic kidney disease. However, the anti-fibrotic effect of evogliptin, a DPP-4 inhibitor, has not been studied. Here, we report the beneficial effects of evogliptin on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice. Evogliptin attenuated UUO-induced renal atrophy and tubulointerstitial fibrosis. Immunohistochemistry and Western blotting demonstrated that evogliptin treatment inhibits pro-fibrotic gene expressions and extracellular matrix production. In vitro findings showed that the beneficial effects of evogliptin on renal fibrosis are mediated by inhibition of the transforming growth factor-β/Smad3 signaling pathway. The present study demonstrates that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin.
|
|
|
KEYWORD
|
|
|
Dipeptidyl-peptidase IV inhibitors, Kidney failure, chronic, Transforming growth factor beta
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|